Navigation Links
Researchers lead search for better drug-addiction treatments
Date:2/2/2011

DALLAS Feb. 3, 2011 UT Southwestern Medical Center psychiatry researchers are leading the Texas arm of a national network that conducts clinical trials aimed at finding effective treatments for drug addiction.

More than 100 community treatment providers and academic medical centers throughout the country are funded in part through the National Institute on Drug Abuse's Clinical Trials Network (CTN). The Texas component includes partnerships between academic and community treatment providers in Dallas, El Paso, Austin and Houston. It is led by Dr. Madhukar Trivedi, professor of psychiatry at UT Southwestern.

"The effects of drugs on the brain are very clear, but we still need long-term answers that cure people who abuse drugs and prevent them from relapse," Dr. Trivedi said. "I applaud NIDA for funding the infrastructure at academic institutions to research therapies in real-world treatment centers that will lead to ready-to-launch cures. Drug abuse affects not just the person, but families and society as a whole."

Each CTN study is conducted in multiple community treatment provider sites across the country, led by a CTN substance abuse researcher and supported by the researchers in the CTN academic institutions affiliated with each participating site.

"It is critical to find new treatments in the substance abuse field where current treatments result in only modest improvements. Finding effective interventions really requires larger, multicenter treatment trials like those occurring in the CTN," Dr. Trivedi said.

One such national study within the CTN is the Stimulant Reduction Intervention Using Dose Exercise (STRIDE), led by Dr. Trivedi. It is a groundbreaking study that tests the short and longer term effectiveness of adding either exercise or health education to treatment as usual in adults who abuse stimulants such as cocaine or methamphetamine. Sites participating in this study in Texas include Nexus Recovery Center and Memorial Hermann Prevention and Recovery Center as well as multiple other sites across the country.

Other studies being conducted in the CTN in Texas include a trial that tests whether an interactive web-based therapy added to usual treatment improves abstinence from drug use, and a trial that examines whether medication, counseling, and incentives to quit smoking added to usual treatment improve abstinence from drug use.

Dr. Trivedi recently received a renewal of the National Institute on Drug Abuse's grant to continue contributions to improve the treatment of addiction for several additional years and said he expects to receive nearly $4 million over the next year.

A national CTN goal for the next few years is to engage other types of medical doctors and treatment settings who treat people addicted to drugs, in research, including primary care, internal medicine and emergency-room physicians. "We will be expanding our reach," Dr. Trivedi said.


'/>"/>

Contact: LaKisha Ladson
lakisha.ladson@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers Craft Blood Vessels for Heart, Kidney Patients
2. Johns Hopkins researchers develop safer way to make induced pluripotent stem cells
3. BUSM researchers involved in first international collaboration on genetics of Alzheimers disease
4. Trained Labrador Can Sniff Out Colon Cancer, Researchers Say
5. Researchers discover signaling pathway crucial to acute lung injury
6. Researchers discover root cause of blood vessel damage in diabetes
7. Researchers discover age of onset of puberty predicts adult osteoporosis risk
8. Ben-Gurion U. researchers determine that a first medical opinion can influence the second
9. Researchers uncover link to increased atherosclerosis risk in lupus patients
10. Princess Margaret Hospital researchers identify a key enzyme that affects radiation response
11. RIC study suggests researchers are entering a new era of advances in brain research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult with ... If so, you may be interested in participating in a research study that focuses ... is to understand more about the relational aspects of adults who have gluten sensitivities ...
(Date:8/19/2017)... Rockville, MD (PRWEB) , ... August 18, 2017 ... ... Food and Drug Administration Reauthorization Act of 2017, legislation that provides for greater ... perceived mild to moderate hearing loss to access OTC hearing aids without being ...
(Date:8/19/2017)... ... August 19, 2017 , ... Yesterday, the President of the ... there are two sides. There are not two sides to hatred, bigotry, discrimination, and ... and prejudice, and the NPEIV stands against all forms of such hatred and discrimination ...
(Date:8/18/2017)... ... August 19, 2017 , ... Mr. Noppadon Pakprot, Deputy Governor ... Thailand Health and Wellness Tourism Showcase 2017 yesterday, which unveiled the latest “Functional ... Tourism Products and Business at TAT said, “Thailand has long been recognized as ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet ... advocating for active, healthy lifestyles and highlighting the importance of proactive eye and ... impairments and shares the latest innovations in hearing aid technology. , In ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... , Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Joel Saban as president, effective Aug. 7, 2017. ... has decided to pursue other interests and will serve as ... tenure, Paul has served us in multiple leadership roles since ... in Jun. 2015 and has provided decisive, strategic leadership which ...
(Date:8/4/2017)... Aug. 3, 2017  Agragen, LLC, a ... in the biopharmaceutical, nutraceutical, and aquacultural feed sectors, ... its lead drug candidates, AGR131.  This drug is ... from the blood of patients suffering from inflammatory ... bowel disease. ...
Breaking Medicine Technology: